Diagnostic de la sclérose latérale amyotrophique idiopathique par spectroscopie infrarouge dans des peaux reconstruites en laboratoire par génie tissulaire
|Abstract:||Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the central nervous system that leads to paralysis and death of patients in two to five years following the diagnosis. Actually, the diagnosis is based on the assessment of clinical symptoms by the neurologist. This makes this disease difficult to diagnose early in its progression, before the first visible clinical symptoms, because of the absence of biomarkers in living patients. The discovery of new biomarkers would be an innovative breakthrough, because it would help in patients’ care. It would also allow an early diagnosis and give the opportunity to follow the disease’s progression over time. This would also help with patients’ stratification and improve clinical trials by forming groups that are more homogeneous. A tissue-engineered skin (TES) model derived from ALS patient’s cells was developed in our team and has already allowed the observation of clinical symptoms that are normally only visible in tissues of the central nervous system after the patient’s death. To discover new biomarkers in skin, infrared spectroscopy was used on these TES. This technique has permitted the observation of differences on some biomolecules between TES derived from ALS patients and TES derived from healthy individuals. Many wavenumbers with different absorptions were attributed to extracellular matrix proteins, secondary structures of proteins, and lipids. These differences allowed to see that there are probably biomarkers for ALS in the skin that could help with this disease’s diagnosis. Further researches will be required to confirm these results and determine with accuracy the presence of biomarkers.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||28 September 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.